|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2005-12-5
|
|
pubmed:abstractText |
Cytotoxic T lymphocyte-associated antigen (CTLA)-4 can inhibit T-cell responses and is involved in tolerance against self antigens. We previously reported autoimmune manifestations and objective cancer regressions in patients with metastatic melanoma treated with CTLA-4 blockade. The possibility of activating tumor-reactive T cells while removing inhibitory activity with CTLA-4 blockade has stimulated interest in using anti-CTLA-4 antibodies in combination with other cancer immunotherapies to improve clinical outcomes. In this study, we assessed the antitumor activity and autoimmune toxicity of CTLA-4 blockade in combination with an immune-activating stimulus, interleukin (IL)-2, in patients with metastatic melanoma.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-10229815,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-10430624,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-10561265,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-10811122,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-10899916,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-10899917,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-11565830,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-12087419,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-12826605,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-1320641,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-15484187,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-16087944,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-16244797,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-1714933,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-2113314,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-7481803,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-8397258,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-8596936,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-8676074,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-8676075,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-8717514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-8759711,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-9058759,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-9354465,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-9449722,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16283570-9742914
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation,
http://linkedlifedata.com/resource/pubmed/chemical/CTLA-4 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/CTLA4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1068-9265
|
|
pubmed:author |
pubmed-author:AttiaPeterP,
pubmed-author:HaworthLeah RLR,
pubmed-author:KammulaUdai SUS,
pubmed-author:KleinerDavidD,
pubmed-author:LevyCatherineC,
pubmed-author:MakerAjay VAV,
pubmed-author:MavroukakisSharon ASA,
pubmed-author:PhanGiao QGQ,
pubmed-author:RosenbergSteven ASA,
pubmed-author:RoyalRichard ERE,
pubmed-author:SherryRichard MRM,
pubmed-author:TopalianSuzanne LSL,
pubmed-author:YangJames CJC,
pubmed-author:YellinMichaelM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1005-16
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16283570-Adult,
pubmed-meshheading:16283570-Antibodies, Monoclonal,
pubmed-meshheading:16283570-Antigens, CD,
pubmed-meshheading:16283570-Antigens, Differentiation,
pubmed-meshheading:16283570-Autoimmunity,
pubmed-meshheading:16283570-CTLA-4 Antigen,
pubmed-meshheading:16283570-Drug Therapy, Combination,
pubmed-meshheading:16283570-Female,
pubmed-meshheading:16283570-Flow Cytometry,
pubmed-meshheading:16283570-Humans,
pubmed-meshheading:16283570-Immunosuppressive Agents,
pubmed-meshheading:16283570-Immunotherapy,
pubmed-meshheading:16283570-Interleukin-2,
pubmed-meshheading:16283570-Male,
pubmed-meshheading:16283570-Melanoma,
pubmed-meshheading:16283570-Middle Aged,
pubmed-meshheading:16283570-Skin Neoplasms,
pubmed-meshheading:16283570-Tomography, X-Ray Computed
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
|
|
pubmed:affiliation |
Surgery Branch, National Cancer Institute, National Institutes of Health, CRC Room 3-3940, 10 Center Drive, MSC 1201, Bethesda, MD 20814, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
